In addition to therapeutic antibodies and immune system modulators, adoptive cell transfer, and immune checkpoint inhibitors represent highly promising strategies for cancer treatment.[45] However, despite the great achievements in ICB therapies focusing on PD‐1, CTLA‐4, and PD‐L1, many patients with solid tumors fail to experience durable clinical benefits. Here, CTLA4 is linked to cancer.